It’s intentional. Managed Care plans are a strange animal. In many ways they are excellent with respect to patient care and information. They are also cost conscious. They want to maximize profit. When you consider how Vascepa reduces long-term healthcare costs per patient (cost to the system), you would think UHC would have kept Vascepa as a covered or even preferred product. However, they look at many things, like patient retention, rebate dollars, costs of generic drugs with the same indication, etc.etc.
For as good as Vascepa is, unfortunately managed care just looks at the bottom line.
Amarin needed to generate a bigger uptake on prescriptions in 2020. In my view scripts didn’t grow as much as I think they should have. Demand would have helped Amarin in the negotiation phase. Plus, a sharp managed care team is always a big help. I don’t know how capable their group is. So, my comment is just a generalization
Market Data 
Markets 
AI
